Skip to main content
Clinical Trials/JPRN-jRCTs031230224
JPRN-jRCTs031230224
Recruiting
Phase 2

Efficacy of oral nutritional supplementation for interstitial lung disease with a tendency to weight loss

Abe Mitsuhiro0 sites25 target enrollmentJuly 13, 2023

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Abe Mitsuhiro
Enrollment
25
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 13, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Abe Mitsuhiro

Eligibility Criteria

Inclusion Criteria

  • 1\) Patients with a diagnosis of interstitial lung disease.
  • 2\) Patients aged 20 years or older at the time of obtaining consent
  • 3\) Patients who have lost at least 2 kg in the last 12 months or have a BMI \<20 kg/m2 in the last 12 months
  • 4\) Patients who have been fully informed of the study and who, on the basis of a thorough understanding of the study, have provided written consent to participate in the study.

Exclusion Criteria

  • 1\) Patients with coexisting malignant diseases
  • 2\) Patients with conditions that may further worsen their nutritional status, such as unstable diabetes mellitus
  • 3\) Patients already taking oral nutritional supplements at least once a week within the last 3 months
  • 4\) Patients receiving new medication within the past month for diarrhoea as a side effect of antifibrotic drugs
  • 5\) Patients allergic to milk, soya or gelatine, which are ingredients of Isocal 100
  • 6\) Patients who cannot give their consent
  • 7\) Other patients who are judged by the study investigator or sub\-investigator to be unsuitable for the safe conduct of the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials